ES555748A0 - Un procedimiento para preparar una vacuna de influenza - Google Patents

Un procedimiento para preparar una vacuna de influenza

Info

Publication number
ES555748A0
ES555748A0 ES555748A ES555748A ES555748A0 ES 555748 A0 ES555748 A0 ES 555748A0 ES 555748 A ES555748 A ES 555748A ES 555748 A ES555748 A ES 555748A ES 555748 A0 ES555748 A0 ES 555748A0
Authority
ES
Spain
Prior art keywords
vaccine
complex
mdp derivative
particle
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES555748A
Other languages
English (en)
Other versions
ES8707113A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Publication of ES555748A0 publication Critical patent/ES555748A0/es
Publication of ES8707113A1 publication Critical patent/ES8707113A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES555748A 1985-06-06 1986-06-05 Un procedimiento para preparar una vacuna de influenza Expired ES8707113A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60123341A JPH0688911B2 (ja) 1985-06-06 1985-06-06 インフルエンザワクチン及びその製造方法

Publications (2)

Publication Number Publication Date
ES555748A0 true ES555748A0 (es) 1987-07-01
ES8707113A1 ES8707113A1 (es) 1987-07-01

Family

ID=14858166

Family Applications (1)

Application Number Title Priority Date Filing Date
ES555748A Expired ES8707113A1 (es) 1985-06-06 1986-06-05 Un procedimiento para preparar una vacuna de influenza

Country Status (12)

Country Link
US (1) US4826687A (es)
EP (1) EP0205098B1 (es)
JP (1) JPH0688911B2 (es)
KR (1) KR940001373B1 (es)
CN (1) CN1020407C (es)
AT (1) ATE76756T1 (es)
AU (1) AU585353B2 (es)
CA (1) CA1262091A (es)
CS (1) CS269981B2 (es)
DE (1) DE3685519T2 (es)
ES (1) ES8707113A1 (es)
SU (1) SU1651782A3 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5897873A (en) * 1984-04-12 1999-04-27 The Liposome Company, Inc. Affinity associated vaccine
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
AU627226B2 (en) * 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
WO1990001947A1 (en) * 1988-08-25 1990-03-08 The Liposome Company, Inc. Affinity associated vaccine
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
WO1991011174A1 (en) * 1990-01-25 1991-08-08 The University Of Colorado Foundation, Inc. Method for preventing immune suppression in trauma patients
JP2777258B2 (ja) * 1990-03-13 1998-07-16 第一製薬株式会社 ムラミルジペプチド含有脂質膜構造体
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
GB9018690D0 (en) * 1990-08-24 1990-10-10 Wellcome Found Vaccines
NZ240369A (en) * 1990-10-30 1993-09-27 Daiichi Seiyaku Co Muramyl dipeptide derivatives and vaccine compositions
JP3836874B2 (ja) * 1994-02-24 2006-10-25 ノババックス インコーポレイテッド 免疫アジュバントとして少ラメラ脂質小胞を含むワクチン
CA2234957C (en) 1995-10-17 2006-12-19 Inge B. Henriksen Insoluble drug delivery
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
IL137734A0 (en) * 1998-02-11 2001-10-31 Res Triangle Pharm Ltd Method and composition for treatment of inflammatory conditions
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
AU764001B2 (en) 1998-05-29 2003-08-07 Skyepharma Canada Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
JP4198318B2 (ja) 1998-08-19 2008-12-17 ヤーゴテック アクチェンゲゼルシャフト プロポフォールの注射可能水性分散物
CA2349203C (en) 1998-11-20 2013-05-21 Rtp Pharma Inc. Dispersible phospholipid stabilized microparticles
CN1174741C (zh) * 1999-09-21 2004-11-10 Rtp药品公司 生物活性物质的表面改性微粒组合物
EP1276465B1 (en) 2000-04-20 2014-03-12 Jagotec AG Improved water-insoluble drug particle process
ATE424811T1 (de) 2000-08-31 2009-03-15 Jagotec Ag Gemahlene partikel
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
AU2001255515A1 (en) * 2000-09-20 2002-04-02 Skyepharma Canada Inc. Stabilised fibrate microparticles
JP2004523552A (ja) * 2001-02-22 2004-08-05 スカイファーマ・カナダ・インコーポレーテッド 低減した摂食−絶食効果を伴うフィブラート−スタチンの組合わせ
PT1361890E (pt) * 2001-02-23 2011-06-07 Glaxosmithkline Biolog Sa Formulações vacinais de influenza para distribuição intradérmica
WO2002087494A2 (en) * 2001-04-27 2002-11-07 Glaxosmithkline Biologicals, Sa Novel vaccine
WO2003002069A2 (en) * 2001-06-29 2003-01-09 Becton, Dickinson And Company Intradermal delivery of vaccines and gene therapeutic agents via microcannula
EP2241330A1 (en) 2003-02-14 2010-10-20 The Curators Of The University Of Missouri Contraceptive methods and compositions related to proteasomal interference
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
TWI329130B (en) 2003-06-19 2010-08-21 Bestewil Holding Bv Functionally reconstituted viral membranes containing adjuvant
BRPI0417225A (pt) * 2003-12-05 2007-03-06 Becton Dickinson Co métodos de aumentar a resposta imune no compartimento intradérmico e compostos úteis nos referidos métodos
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
WO2008112218A2 (en) 2007-03-12 2008-09-18 Antigen Express, Inc. Li-rnai involved li suppression in cancer immunotherapy
WO2009131995A1 (en) * 2008-04-21 2009-10-29 Nanobio Corporation Nanoemulsion influenza vaccine
JP2014520805A (ja) 2011-07-06 2014-08-25 ナノバイオ コーポレーション ヒト呼吸器合胞体ウイルスワクチン
EP2747779A4 (en) 2011-08-22 2015-04-08 Nanobio Corp VACCINE AGAINST HERPES SIMPLEX VIRUS IN THE FORM OF NANOEMULSION

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4009258A (en) * 1972-09-25 1977-02-22 The Mount Sinai School Of Medicine Of The City University Of New York Influenza vaccine containing a recombinant, antigenically hybridized virus and method of using the same
CH589453A5 (es) * 1974-01-14 1977-07-15 Sandoz Ag
US4117113A (en) * 1974-06-25 1978-09-26 National Research Development Corporation Immunological preparations
US4196191A (en) * 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
DE3068743D1 (en) * 1980-01-16 1984-08-30 Weder Hans G Process and dialysis-installation for the preparation of bilayer-vesicles and their use
EP0047480B1 (en) * 1980-09-05 1986-02-05 Institut Armand Frappier Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
US4327182A (en) * 1981-01-22 1982-04-27 Connaught Laboratories Incorporated Purification of influenza sub-unit vaccine
US4565696A (en) * 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
FR2551758B1 (fr) * 1983-08-16 1986-01-31 Anvar Derives de muramyl-peptides et de steroides ayant des proprietes d'activation des macrophages
IL69720A (en) * 1983-09-14 1987-08-31 Univ Ramot Anti-tumor pharmaceutical compositions comprising liposome-bound porphyrins
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions

Also Published As

Publication number Publication date
CS269981B2 (en) 1990-05-14
AU585353B2 (en) 1989-06-15
EP0205098A2 (en) 1986-12-17
AU5836586A (en) 1986-12-18
JPH0688911B2 (ja) 1994-11-09
CN1020407C (zh) 1993-05-05
KR940001373B1 (ko) 1994-02-21
ES8707113A1 (es) 1987-07-01
JPS61282321A (ja) 1986-12-12
CA1262091A (en) 1989-10-03
CS419786A2 (en) 1989-04-14
CN86103717A (zh) 1987-02-11
ATE76756T1 (de) 1992-06-15
SU1651782A3 (ru) 1991-05-23
EP0205098A3 (en) 1989-03-22
DE3685519T2 (de) 1993-01-21
US4826687A (en) 1989-05-02
EP0205098B1 (en) 1992-06-03
DE3685519D1 (de) 1992-07-09
KR870000075A (ko) 1987-02-16

Similar Documents

Publication Publication Date Title
ES555748A0 (es) Un procedimiento para preparar una vacuna de influenza
AU722647B2 (en) Protein-lipid vesicles and autogenous vaccine comprising the same
DK440386A (da) Laegemiddelholdigt chlorfluorcarbon-aerosoldrivmiddelpraeparat
EP0231039A1 (en) Process for preparing immunological complexes and pharmaceutical composition containing these complexes
DK55891D0 (da) Matrix med immunomodulerende virkning
SE8201351L (sv) Sett att framstella liposomberedningar
EP0047480B1 (en) Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
AR001686A1 (es) Una composición vacuna un proceso para prepararla y su uso para la fabricación de una vacuna
CN100556454C (zh) 含有佐剂的功能性重建病毒膜
Ribi et al. Peptides as requirement for immunotherapy of the guinea-pig line-10 tumor with endotoxins
US4148876A (en) Biological preparations
ES8506451A1 (es) Procedimiento para preparar vacunas polivalentes adsorbidas y liofilizadas
AU4324996A (en) Novel cyclodextrin-derivatives and methods for the preparation thereof
Alving et al. Cytotoxic T lymphocytes induced by liposomal antigens: mechanisms of immunological presentation
NO20024571D0 (no) Immunoterapeutiske fremgangsmåter og blandinger
CA2352563A1 (en) Method to produce inactivated w/o emulsion adjuvanted vaccines
ATE130198T1 (de) Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung.
AU769375B2 (en) Vaccine formulation
GR1001093B (el) Απορροφητικό υλικό, μέ?οδος επίτευξης απορροφητικού υλικού, απορροφητικό υπό?εμα, μέ?οδος επίτευξης απορροφητικού υπο?έματος, και απορροφητικό αντικείμενο μιας χρήσεως.
Bergers et al. Critical factors for liposome-incorporated tumour-associated antigens to induce protective tumour immunity to SL2 lymphoma cells in mice
SE8400934L (sv) Forfarande for framstellning av lyofiliserade, adsorberade, polyvalenta vacciner
van Dalen et al. Preparation and characterization of liposomes with incorporated Neisseria gonorrhoeae protein IB and amphiphilic adjuvants
Thibodeau Immunosome technology to improve antigen presentation for efficient and safe viral vaccines
WO1991008771A3 (fr) Procede de culture intensive, in vitro, de souches de babesia divergens, procede de preparation d'exoantigenes et vaccin contenant ces antigenes
Kersten et al. Antigen Carriers: A Success Determining Factor for Subunit Vaccines?

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20020603